Another inhibitor PJ-68 was also developed with an even further increased potency and showed a significant increase in survival in a murine model of BCR-ABL-driven CML and inhibited the in vivo self-renewal of CML leukemia stem cells [30]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.